Ken Griffin Adverum Biotechnologies, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.75 - $1.26 $25,284 - $42,478	33,713 New	33,713 $25,000
Q1 2023 May 15, 2023	SELL	$0.62 - $0.85 $2,354 - $3,227	-3,797 Reduced 47.36%	4,221 $3,000
Q4 2022 Feb 14, 2023	SELL	$0.54 - $10.3 $2,657 - $50,696	-4,922 Reduced 38.04%	8,018 $4,000
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $11,844 - $119,431	-12,338 Reduced 48.81%	12,940 $12,000
Q2 2022 Aug 15, 2022	SELL	$0.81 - $1.34 $41,951 - $69,401	-51,792 Reduced 67.2%	25,278 $31,000
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $251,672 - $398,993	-204,612 Reduced 72.64%	77,070 $101,000
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $56,835 - $78,393	32,664 Added 13.12%	281,682 $495,000
Q3 2021 Nov 15, 2021	SELL	$2.08 - $3.6 $97,970 - $169,563	-47,101 Reduced 15.91%	249,018 $540,000
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $330,949 - $1.04 Million	-98,497 Reduced 24.96%	296,119 $1.04 Million
Q1 2021 May 17, 2021	BUY	$9.26 - $14.36 $911,119 - $1.41 Million	98,393 Added 33.22%	394,616 $3.89 Million
Q4 2020 Feb 16, 2021	SELL	$9.84 - $14.26 $1.24 Million - $1.8 Million	-126,321 Reduced 29.9%	296,223 $3.21 Million
Q3 2020 Nov 16, 2020	SELL	$10.3 - $21.64 $4.55 Million - $9.56 Million	-441,586 Reduced 51.1%	422,544 $4.35 Million
Q2 2020 Aug 14, 2020	SELL	$8.53 - $25.64 $2.38 Million - $7.15 Million	-278,914 Reduced 24.4%	864,130 $18 Million
Q1 2020 May 15, 2020	BUY	$7.98 - $16.32 $7.02 Million - $14.3 Million	879,084 Added 333.04%	1,143,044 $11.2 Million
Q4 2019 Feb 14, 2020	SELL	$5.12 - $12.22 $2.95 Million - $7.05 Million	-576,762 Reduced 68.6%	263,960 $3.04 Million
Q3 2019 Nov 14, 2019	BUY	$5.24 - $15.89 $4.31 Million - $13.1 Million	821,995 Added 4389.36%	840,722 $4.58 Million
Q2 2019 Aug 14, 2019	SELL	$5.1 - $11.89 $8,787 - $20,486	-1,723 Reduced 8.43%	18,727 $223,000
Q1 2019 May 15, 2019	SELL	$3.03 - $6.02 $4.53 Million - $9 Million	-1,494,757 Reduced 98.65%	20,450 $0
Q4 2018 Feb 14, 2019	BUY	$2.87 - $5.92 $2.01 Million - $4.14 Million	698,656 Added 85.56%	1,515,207 $4.77 Million
Q3 2018 Nov 13, 2018	SELL	$4.5 - $7.6 $5.55 Million - $9.38 Million	-1,233,802 Reduced 60.18%	816,551 $0
Q2 2018 Aug 10, 2018	BUY	$5.3 - $6.9 $3.58 Million - $4.66 Million	675,675 Added 49.15%	2,050,353 $0
Q1 2018 May 11, 2018	BUY	$3.65 - $7.95 $4.85 Million - $10.6 Million	1,327,489 Added 2813.13%	1,374,678 $7.97 Million
Q4 2017 Feb 09, 2018	BUY	$2.85 - $3.95 $105,569 - $146,315	37,042 Added 365.05%	47,189 $165,000
Q3 2017 Nov 09, 2017	BUY	$2.45 - $3.65 $24,860 - $37,036	10,147	10,147 $37,000

Others Institutions Holding ADVM

# of Institutions

Shares Held

524K

Call Options Held

Put Options Held

Versant Venture Management, LLC San Francisco, CA

507K
Shares

$3.48 Million
9.32% of portfolio
Pinz Capital Management, LP New York, NY

15.7K
Shares

$107,702
0.03% of portfolio
American Portfolios Advisors Holbrook, NY

1.15K
Shares

$7,889
0.0% of portfolio

View Full List

About Adverum Biotechnologies, Inc.

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $681M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

More about ADVM

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account